Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders

Atherosclerosis

Volumn 168, Issue 1, 2003, Pages 81-89

  Onat, Altan ^a   Hergenç, Gülay ^b   Sansoy, Vedat ^a   Fobker, Manfred ^c   Ceyhan, Köksal ^d   Toprak, Sadik ^a   Assmann, Gerd ^c  

^a ISTANBUL UNIVERSITY   (Turkey)

^b YILDIZ TECHNICAL UNIVERSITY   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

^d DR SIYAMI ERSEK THORACIC AND CARDIOVASCULAR SURGERY TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Apolipoprotein C III; Coronary heart disease; High density lipoprotein; Metabolic syndrome; Triglyceride rich lipoproteins

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN C3; C REACTIVE PROTEIN; CHOLESTEROL; COMPLEMENT COMPONENT C3; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ANALYTICAL PARAMETERS; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CORONARY RISK; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ELECTROCARDIOGRAM; FEMALE; GENDER; HEALTH STATUS; HEALTH SURVEY; HUMAN; HYPERTRIGLYCERIDEMIA; IMMUNOASSAY; INFLAMMATION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; METABOLIC SYNDROME X; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN METABOLISM; RISK ASSESSMENT; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; TURBIDIMETRY; TURKEY (REPUBLIC);

EID: 0038742058     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(03)00025-X     Document Type: Article

References (30)

1. Wang C., McConathy W.J., Kloer H.U., Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins. J. Clin. Invest. 75:1985;384-390.
2. Sacks F.M., Alaupovic P., Moye L.A., Cole T.G., Sussex B., Stampfer M.J., Pfeffer M.A., Braunwald E. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 102:2000;1886-1892.
3. Hodis H.N. Triglyceride-rich lipoprotein remnant particles and risk of atherosclerosis. Circulation. 99:1999;2852-2854. (Editorial).
4. Chivot L., Mainard F., Bigot E., et al. Logistic discriminant analysis of lipids and apolipoproteins in a population of coronary bypass patients and the significance of apolipoproteins C-III and E. Atherosclerosis. 82:1990;205-211.
5. Luc G., Fievet C., Arveiler D., et al. Apolipoproteins C-III and E in apo-B- and non-apo-B-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. J. Lipid Res. 37:1996;508-517.
6. Uiterwaal C.S.P.M., Grobbee D.E., Witteman J.C.M., et al. Postprandial triglyceride response in young adult men and familial risk for coronary atherosclerosis. Ann. Intern. Med. 121:1994;576-583.
7. Ginsberg H.N., Jones J., Blaner W.S., et al. Association of postprandial triglyceride and retinyl palmitate responses with newly diagnosed exercise-induced myocardial ischemia in middle-aged men and women. Arterioscler. Thromb. Vasc. Biol. 15:1995;1829-1838.
8. Thompson G.R. Angiographic evidence for the role of triglyceride-rich lipoproteins in progression of coronary artery disease. Eur. Heart J. 19:(Suppl H):1998;H31-H36.
9. Blankenhorn D.H., Alaupovic P., Wickham E., et al. Prediction of angiographic change in native human coronary arteries and coronary bypass grafts: lipid and nonlipid factors. Circulation. 81:1990;470-476.
10. Mahley R.W., Palaoǧlu E., Atak Z., et al. Turkish Heart Study: lipids, lipoproteins, and apolipoproteins. J. Lipid Res. 36:1995;839-859.
11. Onat A., Yildirim B., Uslu N., et al. Plasma lipoproteins and apolipoproteins in Turkish adults: overall levels, associations with other risk parameters and HDL's role as a marker of coronary risk in women. Arch. Turk. Soc. Cardiol. 27:1999;72-79.
12. Onat A. Risk factors and cardiovascular disease in Turkey. Atherosclerosis. 156:2001;1-10.
13. Onat A., Ceyhan K., Basar Ö., Erer B., Toprak S., Sansoy V. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels - a prospective and cross-sectional evaluation. Atherosclerosis. 165:2002;285-292.
14. Rose G., Blackburn H., Gillum R.F., Prineas R.J. Cardiovascular Survey Methods. 2nd ed. 1982;124-127 WHO, Geneva.
15. Krauss R.M. Atherogenicity of triglyceride-rich lipoproteins. Am. J. Cardiol. 81:(4A):1998;13B-17B.
16. von Eckardstein A., Holz H., Sandkamp M., Weng W., Funke H., Assmann G. Apolipoprotein C-III (Lys58-Glu): identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia. J. Clin. Invest. 87:1991;1724-1731.
17. Marcoux C., Tremblay M., Fredenrich A., Davignon J., Cohn J.S. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins. Metabolism. 50:2001;112-119.
18. Batal R., Tremblay M., Barrett P.H.R., et al. Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects. J. Lipid Res. 41:2000;706-718.
19. Fredenrich A., Giroux L.M., Tremblay M., Krimbou L., Davignon J., Cohn J.S. Plasma lipoprotein distribution of apoC-III in normolipidemic and hypertriglyceridemic subjects: comparison of the apoC-III to apoE ratio in different lipoprotein fractions. J. Lipid Res. 38:1997;1421-1432.
20. Sniderman A., Scantlebury T., Cianflone K. Hypertriglyceridemic hyperapo B: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann. Intern. Med. 135:2001;447-459.
21. Krauss R.M., Herbert P.M., Levy R.I., Frederickson D.S. Further observations on the activation and inhibition of lipoprotein lipase by apolipoproteins. Circ. Res. 33:1973;403-411.
22. Curry M.D., McConathy W.J., Fesmire J.D., Alaupovic P. Quantitative determination of human apolipoprotein C-III by electroimmunoassay. Biochim. Biophys. Acta. 617:1980;503-513.
23. Kinnunen P.K.J., Ehnholm C. Effect of serum and C apoproteins from very low density lipoproteins on human postheparin plasma hepatic lipase. FEBS Lett. 65:1976;354-357.
24. Van Barlingen H.H., de Jong H., Erkelens W., de Bruin T.W.A. Lipoprotein lipase-enhanced binding of human triglyceride-rich lipoproteins to heparan sulfate: modulation by apolipoprotein E and apolipoprotein C. J. Lipid Res. 37:1996;754-763.
25. Windler E., Havel R.J. Inhibitory effect of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver. J. Lipid Res. 26:1985;556-565.
26. Clavey V., Lestavel-Delattre S., Copin C., Bard J.M., Fruchart J.-C. Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII and E. Arterioscler. Thromb. Vasc. Biol. 15:1995;963-971.
27. Mann C.J., Toussard A.A., Yen F.T., et al. Inhibitory effects of specific apolipoprotein C-III isoforms on the binding of triglyceride-rich lipoproteins to the lipolysis-stimulated receptor. J. Biol. Chem. 272:1997;31348-31354.
28. Bersot T.P., Vega G.L., Grundy S.M., et al. Elevated hepatic lipase activity and low levels of high density lipoprotein in a normotriglyceridemic, nonobese Turkish population. J. Lipid Res. 40:1999;432-438.
29. Staels B., Vu-Dac N., Kosykh V.A., Saladin R., Fruchart J.C., Dallongeville J., Auwerx J. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase: a potential mechanism for the hypolipidemic action of fibrates. J. Clin. Invest. 95:1995;705-712.
30. Bisgaier C.L., Essenburg A.D., Barnett B.C., et al. A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor. J. Lipid Res. 39:1998;1317-1330.